The Journal of Immunology, Vol 137, Issue 11 3436-3439, Copyright © 1986 by American Association of Immunologists

ARTICLES

Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis

J Antel, M Bania, A Noronha and S Neely

Activated suppressor cell function, induced with either concanavalin A or OKT3 and mediated by either unfractionated mononuclear cells or "panning" enriched T8+ cells, freshly isolated from peripheral blood, is reduced in patients with progressive multiple sclerosis (MS) as compared with control donors. In this study, we generated T8+ cell lines from the peripheral blood of these same patients and controls. Suppressor activity, mediated by T8+ cells exposed to OKT3 on days 1, 7, and 14 of culture and then treated with mitomycin C on day 16, was significantly reduced in the MS group (mean percent suppression 13% +/- 5) as compared with the control group (68% +/- 6, n = 8, p less than 0.001). No differences were noted in [3H]thymidine uptake by the OKT3- stimulated T8+ cell lines of MS and control groups. Mean percent suppression mediated by T4+ cell lines did not differ between MS and control groups (15% +/- 4, n = 3, vs 22% +/- 2, n = 4). These current data suggest that the previously observed defect in T8+ cell-mediated activated suppressor cell function in MS is a persistent one, favoring the postulate that the defect reflects intrinsic alterations in this cell population rather than a transient effect of serum factors on T8+ cell function.

This article has been cited by other articles:

				D. K. Tennakoon, R. S. Mehta, S. B. Ortega, V. Bhoj, M. K. Racke, and N. J. Karandikar Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis. J. Immunol., June 1, 2006; 176(11): 7119 - 7129. [Abstract] [Full Text] [PDF]

				D N Bourdette, E Edmonds, C Smith, J D Bowen, C R. Guttmann, Z P Nagy, J Simon, R Whitham, J Lovera, V Yadav, et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis Multiple Sclerosis, October 1, 2005; 11(5): 552 - 561. [Abstract] [PDF]

				E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al. Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions Arch Neurol, September 1, 2005; 62(9): 1345 - 1356. [Abstract] [Full Text] [PDF]

				M. A. Friese and L. Fugger Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain, August 1, 2005; 128(8): 1747 - 1763. [Abstract] [Full Text] [PDF]

				A. Matejuk, C. Hopke, A. A. Vandenbark, P. D. Hurn, and H. Offner Middle-Age Male Mice Have Increased Severity of Experimental Autoimmune Encephalomyelitis and Are Unresponsive to Testosterone Therapy J. Immunol., February 15, 2005; 174(4): 2387 - 2395. [Abstract] [Full Text] [PDF]

				M. P. Crawford, S. X. Yan, S. B. Ortega, R. S. Mehta, R. E. Hewitt, D. A. Price, P. Stastny, D. C. Douek, R. A. Koup, M. K. Racke, et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay Blood, June 1, 2004; 103(11): 4222 - 4231. [Abstract] [Full Text] [PDF]

				K. V. Toyka and R. Gold The pathogenesis of CIDP: Rationale for treatment with immunomodulatory agents Neurology, April 22, 2003; 60(90083): S2 - 7. [Abstract] [Full Text]

				J.-M. Vallat, A.F. Hahn, J.-M. Leger, D.P. Cros, L. Magy, F. Tabaraud, P. Bouche, and P.-M. Preux Interferon beta-1a as an investigational treatment for CIDP Neurology, April 22, 2003; 60(90083): S23 - 28. [Abstract] [Full Text]

				S. J. Khoury, C. R. G. Guttmann, E. J. Orav, R. Kikinis, F. A. Jolesz, and H. L. Weiner Changes in Activated T Cells in the Blood Correlate With Disease Activity in Multiple Sclerosis Arch Neurol, August 1, 2000; 57(8): 1183 - 1189. [Abstract] [Full Text] [PDF]